# OnCo record irae-steroid-taper-and-pjp (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/irae-steroid-taper-and-pjp/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "irae-steroid-taper-and-pjp" ;
  schema:name "Steroid taper after immunotherapy side effects, with Pneumocystis prophylaxis and adrenal checks"@en ;
  schema:alternateName "irAE steroid taper"@en, "corticosteroid taper for immune-related adverse events"@en, "PJP prophylaxis on steroids"@en, "PCP prophylaxis immunotherapy"@en, "co-trimoxazole prophylaxis on steroids"@en, "steroid weaning after immunotherapy toxicity"@en ;
  schema:description "Steroids for an immunotherapy side effect are reduced slowly, usually over at least 4 to 6 weeks, because stopping too fast can bring it back. A month or more of higher-dose steroids weakens defences against Pneumocystis pneumonia, so a preventive antibiotic (usually co-trimoxazole) is often given. Your body's own steroid production may need checking before the last tablets stop."@en ;
  schema:url <https://onco.cc/protocols/irae-steroid-taper-and-pjp/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "irae", "infection-prevention" ;
  onco:related <https://onco.cc/protocols/irae-colitis/>, <https://onco.cc/protocols/irae-hepatitis/>, <https://onco.cc/protocols/irae-pneumonitis/>, <https://onco.cc/protocols/irae-hypophysitis-adrenal/>, <https://onco.cc/protocols/irae-rechallenge/>, <https://onco.cc/ideas/idea-bio2-steroid-sparing-irae/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/methylprednisolone/>, <https://onco.cc/drugs/hydrocortisone/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/dostarlimab/> ;
  onco:institutions <https://onco.cc/institutions/sitc/>, <https://onco.cc/institutions/asco/>, <https://onco.cc/institutions/esmo/> ;
  onco:terms <https://onco.cc/terms/irae/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/> .